drugset
drugset / Trial / NCT03230864

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

NCT03230864 ↗

Phase 3 Terminated 119 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the efficacy of 10 mg/day Lu AF35700 on symptoms of schizophrenia in patients with early-in-disease (ED) or late-in-disease (LD) treatment-resistant schizophrenia (TRS)

Timeline

Start
2017-07-20
Primary completion
2018-12-23
Completion
2019-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF35700 Unknown 10 mg Oral
Background Olanzapine Small molecule 15 mg Oral
Background Olanzapine Small molecule 20 mg Oral
Background Risperidone Other / unclassified 4 mg Oral
Background Risperidone Other / unclassified 6 mg Oral

Indications

schizophrenia